CJC-1295 research guide for Espavé. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
CJC-1295 isn't found on pharmacy shelves in Espavé or anywhere else for that matter — it's a research compound supplied via a dedicated online market. This global online supply model is ultimately a quality advantage — top vendors differentiate through analytical documentation in ways local stores never could. Separating properly characterised CJC-1295 from the rest of the market depends on three things: an HPLC chromatogram documenting ≥98% purity, mass spec data establishing the correct molecular weight, and a batch-specific endotoxin panel. What follows is a practical research guide built specifically around CJC-1295, covering everything a Espavé researcher needs to evaluate quality systematically.
The Science Behind CJC-1295
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Espavé researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
How to Evaluate CJC-1295 Vendors
Evaluating CJC-1295 vendors begins with the COA: request the batch-specific certificate before purchasing, not after. The HPLC analytical chromatogram is the most important document in the COA: it should show a dominant main peak representing CJC-1295, with minimal secondary peaks representing impurities — purity should be stated as ≥98%. Negative indicators in CJC-1295 vendor evaluation: prices more than 30-40% below standard market rates, no information about manufacturing source, no community presence, and COAs that omit endotoxin testing. Price is an ineffective primary criterion for CJC-1295 quality — research-grade synthesis and testing has genuine production costs that cannot be cut without consequences, so the lowest-priced options almost always involve trade-offs.
Order CJC-1295 — ships to Espavé
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not completed the clinical trial process required for pharmaceutical approval — its safety profile is based on preclinical research and restricted human research data. Reconstitute CJC-1295 with bacteriostatic water at the concentration suited to your research design; a standard 5mg reconstituted in 2mL produces 2.5mg/mL — or 25mcg per insulin syringe unit. Verify the endotoxin level in your CJC-1295 batch COA before use in any in-vivo protocol — look for results stated as EU/mg and verify they are within the acceptable range for your research context. For any individual considering CJC-1295 outside a formal research context: seek medical advice first — this compound is not a licensed human medication and its risk profile is not equivalent to approved medications.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
